

[Acetylsalicylic acid](#)

Essential medicine status

Section:

[29. Medicines for diseases of joints](#) [29.3. Medicines for juvenile joint diseases](#)

ATC codes: [N02BA01](#)

EMLc

Indication

Mucocutaneous lymph node syndrome ICD11 code: [4A44.5](#)

Medicine type

Chemical agent

List type

Complementary

Additional notes

Acute or chronic use for rheumatic fever, juvenile arthritis , Kawasaki disease

Formulations

**Local > Rectal > Suppository:** 150 mg ; 300 mg

**Oral > Solid > dispersible tablet:** 75 mg ; 300 mg ; 500 mg

**Oral > Solid > tablet:** 75 to 500 mg

EML status history

First added in 2007 ([TRS 950](#))

Changed in 2013 ([TRS 985](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents.](#)

Wikipedia

[Acetylsalicylic acid](#)

DrugBank

[Acetylsalicylic acid](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes to the listing of acetylsalicylic acid: - the lower strength of the range of strengths for acetylsalicylic acid tablets be changed from 100 mg to 75 mg; - removal of the 50 mg strength of suppositories, and addition of 300 mg strength of suppositories; - addition of dispersible tablets (75 g, 300 mg and 500 mg) to facilitate dosing in children unable to swallow solid tablets.